Stay updated on Tepotinib & Gefitinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.

Latest updates to the Tepotinib & Gefitinib in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe page revision history shows removal of v3.4.1 and addition of v3.4.2; there are no changes to the study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision badge updated from v3.4.0 to v3.4.1 on the page. No substantive content or functionality changes were detected.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no changes to study content or user-facing features were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check69 days agoChange DetectedAn administrative revision tag 'Revision: v3.3.3' was added and the 'HHS Vulnerability Disclosure' link along with the previous 'Revision: v3.3.2' were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check91 days agoChange DetectedPublications section updated to clarify that publications are provided voluntarily by the person entering study information. The revision tag is updated to v3.3.2, replacing the old v3.2.0 wording.SummaryDifference0.1%

- Check98 days agoChange DetectedThe page no longer shows the site-wide government funding status notice. The study details and data presented on the page remain unchanged.SummaryDifference0.2%

Stay in the know with updates to Tepotinib & Gefitinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.